All In Biotech

NDA 022574 · Bayer Hlthcare

Safyral

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium · Oral

Last checked: Nov 20, 2026Latest source record: May 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Dec 16, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

146

48 Phase 3, 7 recruiting

FAERS reports

246

145 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium. ( 4 ) • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

What it is approved for

From the label in effect Mar 4, 2026.

Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) 1.1 Oral Contraceptive Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium is indicated for use by females of reproductive potential to prevent pregnancy. 1.2 Folate Supplementation Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium is indicated in females of reproductive potential who choose to use an oral contraceptive as their method of contraception, to raise folate levels for the purpose of reducing the risk of a neural tube defect in a pregnancy conceived while taking the product or shortly after discontinuing the product.

Mechanism: COCs lower the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SAFYRAL · DROSPIRENONE 3MG,N/A; ETHINYL ESTRADIOL 0.03MG,N/A; LEVOMEFOLATE CALCIUM 0.451MG,0.451MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • injury67
  • pulmonary embolism65
  • deep vein thrombosis64
  • pain45
  • emotional distress41
  • anxiety33
  • general physical health deterioration28
  • anhedonia27
  • off label use18
  • drug dose omission14
  • thrombosis13
  • metrorrhagia10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
201124
201251
201361
201456
201527
201612
20176
20182
20191
20202
20212
20231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Safyral (Drospir/Eth Estra/Levomefol Ca)

2024 spending

$6K

Beneficiaries

n/a

20 claims

Per beneficiary

n/a

$6.95 per unit

View as table
YearSpending
2020$2,633
2021$3,353
2022$0
2023$7,555
2024$5,836

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 311 on PubMed

Sponsor: Bayer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.